NCT06609109 Effect of Cannabis on E-Cigarette Use Behavior
| NCT ID | NCT06609109 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Johns Hopkins University |
| Condition | Cannabis Use |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-03-19 |
| Primary Completion | 2029-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 100 participants in total. It began in 2025-03-19 with a primary completion date of 2029-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine the impact of tetrahydrocannabinol (THC) administration on motivational, subjective, and physiological effects of electronic cigarettes. The study's goals are to test demand for e-cigarettes, tobacco craving, affect, heart rate, blood pressure, expired breath carbon monoxide, and cognitive performance. Researchers will compare multiple doses of THC and a placebo in participants who smoke e-cigarettes and either smoke or vape THC in the laboratory.
Eligibility Criteria
Inclusion criteria: 1. Healthy non-treatment seeking adults aged 21 or older 2. Report daily use of e-cigarettes 3. Biological confirmation of e-cigarette use: have a positive urine cotinine test at screening 4. Report current use of cannabis (at least 1 occasion per week) 5. Have experience with the inhalation route of administration for cannabis 6. Biological confirmation of cannabis use: have a positive urinary THC drug test at screening. 7. For women of children bearing potential and men with female partners of child-bearing potential, must be willing to use an effective form of contraception during the study. Exclusion criteria: 1. Report current intention to reduce or quit cannabis or tobacco use within the next 30 days 2. Meet Diagnostic and Statistical Manual (DSM-5) criteria for a substance use disorder other than alcohol, cannabis, or nicotine 3. Test positive for illicit drugs other than cannabis and tobacco 4. Positive breath alcohol test at study admission 5. Have a current physical or mental illness judged by the study team to negatively impact participant safety or scientific integrity 6. Have a lifetime history of suicidal behavior (i.e. past suicide attempt), or current suicidal behavior or ideation as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) 7. Are currently pregnant, planning to become pregnant in the next three months or are currently breastfeeding 8. Have a history of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina) 9. Are currently enrolled in another clinical trial or have received any drug as part of a research study within 30 days of study participation.
Contact & Investigator
Dustin Lee, PhD
PRINCIPAL INVESTIGATOR
Johns Hopkins School of Medicine
Frequently Asked Questions
Who can join the NCT06609109 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Cannabis Use. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06609109 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06609109 currently recruiting?
Yes, NCT06609109 is actively recruiting participants. Contact the research team at lmorri20@jhmi.edu for enrollment information.
Where is the NCT06609109 trial being conducted?
This trial is being conducted at Baltimore, United States.
Who is sponsoring the NCT06609109 clinical trial?
NCT06609109 is sponsored by Johns Hopkins University. The principal investigator is Dustin Lee, PhD at Johns Hopkins School of Medicine. The trial plans to enroll 100 participants.